Central Bank & Trust Co. Buys New Holdings in Boston Scientific Co. (NYSE:BSX)

Central Bank & Trust Co. bought a new position in Boston Scientific Co. (NYSE:BSX - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 8,242 shares of the medical equipment provider's stock, valued at approximately $831,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Park Avenue Securities LLC boosted its stake in Boston Scientific by 258.1% in the 1st quarter. Park Avenue Securities LLC now owns 46,082 shares of the medical equipment provider's stock worth $4,649,000 after purchasing an additional 33,213 shares during the period. OLD National Bancorp IN acquired a new stake in Boston Scientific during the 1st quarter valued at $203,000. Bank of New Hampshire lifted its holdings in shares of Boston Scientific by 17.9% in the first quarter. Bank of New Hampshire now owns 3,025 shares of the medical equipment provider's stock valued at $305,000 after purchasing an additional 460 shares in the last quarter. Miracle Mile Advisors LLC boosted its position in shares of Boston Scientific by 9.6% in the first quarter. Miracle Mile Advisors LLC now owns 6,025 shares of the medical equipment provider's stock worth $608,000 after buying an additional 527 shares during the period. Finally, Revolve Wealth Partners LLC purchased a new position in shares of Boston Scientific during the first quarter valued at $252,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 56,372 shares of the firm's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total value of $5,799,551.36. Following the sale, the executive vice president now directly owns 178,342 shares in the company, valued at $18,347,824.96. This trade represents a 24.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Vance R. Brown sold 4,826 shares of the company's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the transaction, the senior vice president now directly owns 36,193 shares of the company's stock, valued at $3,441,592.37. This represents a 11.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 411,970 shares of company stock worth $42,406,693 over the last three months. 0.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BSX has been the topic of several recent analyst reports. Robert W. Baird upped their price target on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Truist Financial lifted their target price on Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Morgan Stanley increased their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Finally, Argus set a $130.00 price objective on shares of Boston Scientific in a research report on Tuesday, February 18th. Twenty-one investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $116.00.

Boston Scientific Stock Performance

Boston Scientific stock traded down $0.79 on Friday, reaching $102.04. 9,114,389 shares of the stock were exchanged, compared to its average volume of 6,465,530. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a twelve month low of $71.88 and a twelve month high of $107.17. The firm has a fifty day moving average price of $100.49 and a two-hundred day moving average price of $98.43. The stock has a market cap of $150.96 billion, a PE ratio of 81.63, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The business had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same quarter in the previous year, the firm earned $0.56 EPS. The firm's revenue was up 20.9% compared to the same quarter last year. Sell-side analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.